

ModernGraham Valuation

Company Name:

Hologic, Inc.

Company Ticker HOLX

Date of Analysis

6/10/2018



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$10,467,240,056	Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	1.26	Fail
3. Earnings Stability	Positive EPS for 10 years prior		Fail
4. Dividend Record	Dividend Payments for 10 years prior		Fail
	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	-147.29%	Fail
5. Earnings Growth	PEmg < 20	36.87	Fail
6. Moderate PEmg Ratio	PB Ratio < 2.5 OR PB*PEmg < 50	4.34	Fail
7. Moderate Price to Assets			

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	1.26	Fail
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	8.16	Fail
3. Earnings Stability	Positive EPS for 5 years prior		Pass
4. Dividend Record	Currently Pays Dividend		Fail
5. Earnings Growth	EPSmg greater than 5 years ago Score		Pass

Suitability

Defensive	No
Enterprising	No

Stage 2: Determination of Intrinsic Value

EPSmg	\$1.04
MG Growth Estimate	15.00%
MG Value	\$40.04
MG Value based on 3% Growth	\$15.08
MG Value based on 0% Growth	\$8.84
Market Implied Growth Rate	14.18%

MG Opinion

Current Price	\$38.34
% of Intrinsic Value	95.75%
Opinion	Fairly Valued
MG Grade	D+

Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	-\$11.38
Graham Number	\$5.23
PEmg	36.87
Current Ratio	1.26
PB Ratio	4.34
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Useful Links:

ModernGraham tagged articles	Morningstar
Google Finance	MSN Money
Yahoo Finance	Seeking Alpha
GuruFocus	SEC Filings

EPS History		EPSmg History	
Next Fiscal Year Estimate		Next Fiscal Year Estimate	
Sep2017	\$0.12	Sep2017	\$1.04
Sep2016	\$2.64	Sep2016	\$1.00
Sep2015	\$1.16	Sep2016	-\$0.08
Sep2015	\$0.45	Sep2015	-\$0.70
Sep2014	\$0.06	Sep2014	-\$1.14
Sep2013	-\$4.36	Sep2013	-\$2.02
Sep2012	-\$0.28	Sep2012	-\$1.24
Sep2011	\$0.59	Sep2011	-\$1.75
Sep2010	-\$0.24	Sep2010	-\$2.56
Sep2009	-\$8.64	Sep2009	-\$3.07
Sep2008	-\$1.57	Sep2008	-\$0.19
Sep2007	\$0.86	Sep2007	\$0.45
Sep2006	\$0.28	Sep2006	\$0.21
Sep2005	\$0.32	Sep2005	\$0.13
Sep2004	\$0.15	Sep2004	-\$0.01
Sep2003	\$0.04	Sep2003	-\$0.10
Sep2002	\$0.00	Sep2002	-\$0.15
Sep2001	-\$0.34	Balance Sheet Information	
Sep2000	-\$0.31	3/1/2018	
Sep1999	-\$0.07	Total Current Assets	\$1,635,200,000
Sep1998	\$0.19	Total Current Liabilities	\$1,299,600,000
		Long-Term Debt	\$2,739,200,000
		Total Assets	\$7,234,400,000
		Intangible Assets	\$5,041,900,000
		Total Liabilities	\$4,788,800,000
		Shares Outstanding (Diluted Average)	277,114,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other [Hologic Inc Valuation – Initial Coverage \\$HOLX](#)

ModernGraham
posts about the
company

Other [Mettler-Toledo International Inc Valuation – June 2018 \\$MTD](#)

ModernGraham [Envision Healthcare Corp Valuation – June 2018 \\$EVHC](#)

posts about related [DaVita Inc Valuation – June 2018 \\$DVA](#)

companies [Danaher Corp Valuation – May 2018 \\$DHR](#)

[Agilent Technologies Inc Valuation – May 2018 \\$A](#)

[Cooper Companies Inc Valuation – May 2018 \\$COO](#)

[Edwards Lifesciences Corp Valuation – May 2018 \\$EW](#)

[Baxter International Inc Valuation – May 2018 \\$BAX](#)

[Boston Scientific Corp Valuation – May 2018 \\$BSX](#)

[Centene Corp Valuation – May 2018 \\$CNC](#)